Literature DB >> 11122701

Gene therapy for atherosclerosis and atherosclerosis-related diseases.

T Pakkanen1, S Ylä-Herttuala.   

Abstract

Gene therapy for atherosclerosis-related disorders of lipoprotein metabolism is primarily directed to liver and aims at long-lasting correction of familial hypercholesterolemia, lipoprotein / hepatic lipase deficiency, and Apolipoprotein A, B, or E -related diseases. Treatment of complications of atherosclerosis (eg, restenosis, ischemia) requires local gene transfer to arterial wall or ischemic muscle with transient gene expression. Catheter-mediated approach or direct injections have been used in clinical trials for the treatment of restenosis and for the induction of angiogenesis in ischaemic limb and myocardium. Other possible applications of local gene transfer include antithrombotic treatment and stabilization of vulnerable plaques.

Entities:  

Mesh:

Year:  1999        PMID: 11122701     DOI: 10.1007/s11883-999-0008-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.967


  81 in total

1.  Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene.

Authors:  T Arai; N Wang; M Bezouevski; C Welch; A R Tall
Journal:  J Biol Chem       Date:  1999-01-22       Impact factor: 5.157

Review 2.  Liver-directed gene transfer vectors.

Authors:  N Ferry; J M Heard
Journal:  Hum Gene Ther       Date:  1998-09-20       Impact factor: 5.695

3.  Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits.

Authors:  K F Kozarsky; D K Bonen; F Giannoni; T Funahashi; J M Wilson; N O Davidson
Journal:  Hum Gene Ther       Date:  1996-05-20       Impact factor: 5.695

4.  VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries.

Authors:  M Laitinen; I Zachary; G Breier; T Pakkanen; T Häkkinen; J Luoma; H Abedi; W Risau; M Soma; M Laakso; J F Martin; S Ylä-Herttuala
Journal:  Hum Gene Ther       Date:  1997-10-10       Impact factor: 5.695

5.  Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins.

Authors:  S J George; A H Baker; G D Angelini; A C Newby
Journal:  Gene Ther       Date:  1998-11       Impact factor: 5.250

6.  Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.

Authors:  M W Chang; E Barr; M M Lu; K Barton; J M Leiden
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

7.  Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture.

Authors:  P R Moreno; E Falk; I F Palacios; J B Newell; V Fuster; J T Fallon
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

8.  An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.

Authors:  J R Wetterau; R E Gregg; T W Harrity; C Arbeeny; M Cap; F Connolly; C H Chu; R J George; D A Gordon; H Jamil; K G Jolibois; L K Kunselman; S J Lan; T J Maccagnan; B Ricci; M Yan; D Young; Y Chen; O M Fryszman; J V Logan; C L Musial; M A Poss; J A Robl; L M Simpkins; W A Slusarchyk; R Sulsky; P Taunk; D R Magnin; J A Tino; R M Lawrence; J K Dickson; S A Biller
Journal:  Science       Date:  1998-10-23       Impact factor: 47.728

9.  A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.

Authors:  M Grossman; D J Rader; D W Muller; D M Kolansky; K Kozarsky; B J Clark; E A Stein; P J Lupien; H B Brewer; S E Raper
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

10.  Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo.

Authors:  L L Shears; M R Kibbe; A D Murdock; T R Billiar; A Lizonova; I Kovesdi; S C Watkins; E Tzeng
Journal:  J Am Coll Surg       Date:  1998-09       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.